Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Observational studies have already reported the risk of serious infections in rheumatoid arthritis (RA) treated with tocilizumab but in limited samples. The aim of this study was to investigate the predictive risk factors of serious infections in the largest European registry of patients treated with tocilizumab for RA.
Methods: 1491 RA patients included in the French REGistry –RoAcTEmra (REGATE) were analysed to calculate incidence rate of severe infections and to identify independent factors associated with severe infections. Kaplan -Meier method was used to assess probability of remaining severe infection-free. Cox models were performed to identify independent factors associated with severe infections. Variables showing bivariate association with the dependent variable with a P value less than 0.15 were entered into the multivariate model. Multiple imputation was used to compensate missing data in some variables. A P value <0.05 was considered statistically significant.
Conclusion: The rate of severe infections in current practice is similar to that reported in clinical trials. High PMN above 4.5 G/L at baseline and negative ACPA are predictive factors of serious infection requiring in this case a tighter surveillance.
To cite this abstract in AMA style:Morel J, CONSTANTIN A, Baron G, Dernis E, Flipo RM, Rist Bouillon S, Combe B, Gottenberg JE, Schaeverbeke T, Soubrier M, Vittecoq O, Dougados M, Saraux A, Mariette X, Ravaud P, Sibilia J. Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate (REGISTRY –ROACTEMRA) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/risk-factors-of-severe-infections-in-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-in-the-french-registry-regate-registry-roactemra/. Accessed November 29, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-of-severe-infections-in-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-in-the-french-registry-regate-registry-roactemra/